Taiwan Biomaterial Co., Ltd. (TPEX:6649)

Market Cap	3.10B
Revenue (ttm)	157.98M
Net Income (ttm)	27.08M
Shares Out	42.00M
EPS (ttm)	0.64
PE Ratio	115.29
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,422,389
Average Volume	779,306
Open	74.50
Previous Close	70.50
Day's Range	71.10 - 75.70
52-Week Range	29.65 - 75.70
Beta	0.67
RSI	68.01
Earnings Date	Nov 7, 2025

About Taiwan Biomaterial

Taiwan Biomaterial Co., Ltd. engages in the development and sale of medical devices in Taiwan. The company provides Foamagen, a foamy dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and the nickel-titanium guidewire for guiding cerebral vascular surgery; and tissue repair and regeneration products for the treatment of early osteoarthritis. Taiwan Biomaterial Co., Ltd. Was founded in 2010 and is based in Zhubei, Taiwan.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 35
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6649

Financial Performance

In 2024, Taiwan Biomaterial's revenue was 96.57 million, an increase of 32.59% compared to the previous year's 72.84 million. Losses were -1.73 million, -82.90% less than in 2023.